- Home
- HBANL vs CGEN Comparison
HBANL vs CGEN Comparison
Compare HBANL & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBANL
- CGEN
- Stock Information
- Founded
- HBANL N/A
- CGEN 1993
- Country
- HBANL United States
- CGEN Israel
- Employees
- HBANL 20043
- CGEN N/A
- Industry
- HBANL Major Banks
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HBANL Finance
- CGEN Health Care
- Exchange
- HBANL Nasdaq
- CGEN Nasdaq
- Market Cap
- HBANL N/A
- CGEN 134.3M
- IPO Year
- HBANL N/A
- CGEN 2000
- Fundamental
- Price
- HBANL $26.10
- CGEN $1.65
- Analyst Decision
- HBANL
- CGEN Strong Buy
- Analyst Count
- HBANL 0
- CGEN 1
- Target Price
- HBANL N/A
- CGEN $4.00
- AVG Volume (30 Days)
- HBANL N/A
- CGEN 470.1K
- Earning Date
- HBANL N/A
- CGEN 11-12-2024
- Dividend Yield
- HBANL N/A
- CGEN N/A
- EPS Growth
- HBANL N/A
- CGEN N/A
- EPS
- HBANL N/A
- CGEN 0.02
- Revenue
- HBANL N/A
- CGEN $59,852,000.00
- Revenue This Year
- HBANL N/A
- CGEN $57.27
- Revenue Next Year
- HBANL N/A
- CGEN N/A
- P/E Ratio
- HBANL N/A
- CGEN $85.40
- Revenue Growth
- HBANL N/A
- CGEN 698.03
- 52 Week Low
- HBANL N/A
- CGEN $1.35
- 52 Week High
- HBANL N/A
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- HBANL 52.45
- CGEN 56.57
- Support Level
- HBANL $25.20
- CGEN $1.47
- Resistance Level
- HBANL $26.23
- CGEN $1.65
- Average True Range (ATR)
- HBANL 0.42
- CGEN 0.10
- MACD
- HBANL -0.01
- CGEN 0.00
- Stochastic Oscillator
- HBANL 82.57
- CGEN 80.80
About HBANL Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred Stock
Huntington is a regional us bank with around $200 billion in assets (as of September 2024) and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.